Publications by authors named "Issei Saeki"

Claim this Profile
E
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.
Ryu Sasaki, Shigeo Shimose, Issei Saeki, Takanori Ito, Yasuto Takeuchi

Liver Int· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.
Takeshi Hatanaka, Shigeo Shimose, Takanori Ito, Joji Tani, Tetsu Tomonari, Issei Saeki

Hepatol Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.
Takanori Ito, Shigeo Shimose, Issei Saeki, Yasuto Takeuchi, Joji Tani

J Gastroenterol Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma.
Issei Saeki, Yutaka Suehiro, Yurika Yamauchi, Norikazu Tanabe, Toshihiko Matsumoto

Hepatol Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caution Regarding Short-Term Increases in Ammonia Levels Following Splenic Artery Embolization.
Tsuyoshi Ishikawa, Aika Kirihara, Natsuko Nishiyama, Maho Egusa, Tsuyoshi Fujioka, Issei Saeki

Hepatol Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan.
Shigeo Shimose, Issei Saeki, Takanori Ito, Yasuto Takeuchi, Joji Tani

Hepatol Int· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma.
Tetsu Tomonari, Shigeo Shimose, Issei Saeki, Joji Tani, Yuichi Honma

Hepatol Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early-onset diabetes with low utilization of lipid as an energy source carrying a rare missense mutation in the CEL gene.
Ayana Fujii, Hiroko Nakabayashi, Yuko Nagao, Masaru Akiyama, Akihiko Taguchi, Issei Saeki

Endocrinol Diabetes Metab Case Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction hepatic arterial infusion chemotherapy followed by surgery for hepatocellular carcinoma with massive portal vein tumor thrombosis: a case series of 20 patients.
Yuta Kimura, Yukio Tokumitsu, Yoshitaro Shindo, Hiroto Matsui, Satoshi Matsukuma, Issei Saeki

J Med Case Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to the Letter regarding "Combination Assay of Methylated with Tumor Markers for Detection of Early-Stage Hepatocellular Carcinoma".
Yuki Kunimune, Yutaka Suehiro, Issei Saeki, Kiyoshi Ichihara, Teppei Yamashita

Liver Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.
Takanori Ito, Shigeo Shimose, Joji Tani, Tetsu Tomonari, Issei Saeki

Hepatol Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma.
Norikazu Tanabe, Issei Saeki, Kenji Yamaoka, Tomokazu Kawaoka, Tetsu Tomonari

Anticancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Assay of Methylated with Tumor Markers Shows High Sensitivity for Detection of Early-Stage Hepatocellular Carcinoma.
Yuki Kunimune, Yutaka Suehiro, Issei Saeki, Yurika Yamauchi, Norikazu Tanabe

Liver Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Varying Impact of Lenvatinib or Sorafenib Therapy on Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma.
Yurika Yamauchi, Issei Saeki, Koichi Fujisawa, Maho Egusa, Natsuko Nishiyama

Oncology· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
Issei Saeki, Shigeo Shimose, Tetsu Tomonari, Takanori Ito, Joji Tani

PLoS One· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.
Shigeo Shimose, Issei Saeki, Tetsu Tomonari, Takanori Ito, Joji Tani

Oncol Lett· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, Toru Ishikawa, Yoshitaka Inaba

Liver Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.
Issei Saeki, Yutaka Suehiro, Yurika Yamauchi, Tomomi Hoshida, Norikazu Tanabe

Hepatol Int· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Yurika Yamauchi, Issei Saeki, Takahiro Yamasaki, Maho Egusa, Natsuko Nishiyama

Hepatol Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy.
Issei Saeki, Takahiro Yamasaki, Yurika Yamauchi, Tomokazu Kawaoka, Shinsuke Uchikawa

Cancer Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma.
Norikazu Tanabe, Issei Saeki, Yuki Aibe, Takashi Matsuda, Tadasuke Hanazono

Cancers (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension.
Tsuyoshi Ishikawa, Maho Egusa, Tsuyoshi Fujioka, Natsuko Nishiyama, Daiki Kawamoto, Issei Saeki

J Gastroenterol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment.
Takahiro Yamasaki, Issei Saeki, Yurika Yamauchi, Toshihiko Matsumoto, Yutaka Suehiro

Liver Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening for portopulmonary hypertension using computed tomography-based measurements of the main pulmonary artery and ascending aorta diameters in patients with portal hypertension.
Tsuyoshi Ishikawa, Maho Egusa, Daiki Kawamoto, Tatsuro Nishimura, Ryo Sasaki, Issei Saeki

Hepatol Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma.
Issei Saeki, Takahiro Yamasaki, Yurika Yamauchi, Taro Takami, Tomokazu Kawaoka

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis